Sort   by:  
 Page size 
UnknownHealth benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Not available
S-EPMC4114402 | biostudies-literature
UnknownNucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Not available
S-EPMC5555436 | biostudies-literature
UnknownMaraviroc for previously treated patients with R5 HIV-1 infection.
Not available
S-EPMC3078519 | biostudies-literature
UnknownViral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.
Not available
S-EPMC2745911 | biostudies-literature
UnknownComparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.
Not available
S-EPMC4643831 | biostudies-literature
UnknownFactors associated with D-dimer levels in HIV-infected individuals.
Not available
S-EPMC3953205 | biostudies-literature
UnknownSeverity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.
Not available
S-EPMC4309077 | biostudies-literature
Sort   by:  
 Page size